Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients

Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients

BACKGROUND:In breast cancer endocrine therapy, post-therapy Ki-67 assay of biopsy material predicts recurrence-free survival but is invasive and prone to sampling error. 18F]Fluorodeoxyglucose (FDG) positron emission tomography (PET) has shown an early agonist or 'flare' response to tamoxi...

Full description

Bibliographic Details
Main Authors: Kurland, Brenda, Gadi, Vijayakrishna, Specht, Jennifer, Allison, Kimberly, Livingston, Robert, Rodler, Eve, Peterson, Lanell, Schubert, Erin, Chai, Xiaoyu, Mankoff, David, Linden, Hannah
Other Authors: Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA
Language:en
Published: BioMed Central 2012
Subjects:
FDG PET
Ki-67
Breast cancer
Aromatase inhibitor
Trastuzumab
Pharmacodynamic response Early response
Online Access:Kurland et al. EJNMMI Research 2012, 2:34 http://www.ejnmmires.com/content/2/1/34
http://hdl.handle.net/10150/610135
http://arizona.openrepository.com/arizona/handle/10150/610135

Internet

Kurland et al. EJNMMI Research 2012, 2:34 http://www.ejnmmires.com/content/2/1/34
http://hdl.handle.net/10150/610135
http://arizona.openrepository.com/arizona/handle/10150/610135

Similar Items